- Report
- January 2024
- 200 Pages
Global
From €4856EUR$5,000USD£4,189GBP
- Report
- November 2023
- 175 Pages
Global
From €4856EUR$5,000USD£4,189GBP
- Report
- February 2024
- 120 Pages
Global
From €4614EUR$4,750USD£3,980GBP
- Report
- February 2024
- 112 Pages
Global
From €4614EUR$4,750USD£3,980GBP
- Clinical Trials
- April 2024
- 180 Pages
Global
From €2914EUR$3,000USD£2,514GBP
- Clinical Trials
- April 2024
- 150 Pages
Global
From €1943EUR$2,000USD£1,676GBP
- Drug Pipelines
- April 2024
- 150 Pages
Global
From €2428EUR$2,500USD£2,095GBP
- Clinical Trials
- April 2024
- 250 Pages
Global
From €2914EUR$3,000USD£2,514GBP
- Report
- June 2023
- 245 Pages
Global
From €7284EUR$7,500USD£6,284GBP
- Report
- May 2023
- 220 Pages
Global
From €2428EUR$2,500USD£2,095GBP
- Report
- October 2023
- 145 Pages
Global
From €3059EUR$3,150USD£2,639GBP
- Report
- July 2023
- 290 Pages
Global
From €3497EUR$3,600USD£3,016GBP
- Report
- February 2022
- 360 Pages
United States
From €3497EUR$3,600USD£3,016GBP
- Report
- March 2021
- 240 Pages
United States
From €2914EUR$3,000USD£2,514GBP
- Report
- January 2023
- 189 Pages
Global
From €4079EUR$4,200USD£3,519GBP
- Report
- September 2022
- 239 Pages
Global
From €7284EUR$7,500USD£6,284GBP
- Clinical Trials
- August 2022
- 150 Pages
Global
From €2428EUR$2,500USD£2,095GBP
- Report
- February 2022
- 308 Pages
Global
From €9227EUR$9,500USD£7,960GBP
- Drug Pipelines
- January 2022
- 200 Pages
Global
From €7284EUR$7,500USD£6,284GBP
- Report
- January 2022
- 224 Pages
Global
From €6750EUR$6,950USD£5,823GBP
Ramucirumab is a monoclonal antibody used in the treatment of certain types of cancer. It is used in combination with other drugs to treat metastatic gastric cancer, metastatic non-small cell lung cancer, and metastatic colorectal cancer. It works by blocking the action of a protein called vascular endothelial growth factor (VEGF), which helps cancer cells grow and spread. Ramucirumab is approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Ramucirumab is a relatively new drug in the oncology market, but it has been gaining traction in recent years. It is used in combination with other drugs to treat a variety of cancers, and it has been shown to be effective in prolonging survival in some patients. It is also being studied in combination with other drugs for the treatment of other types of cancer.
Some of the companies in the Ramucirumab market include Eli Lilly, AstraZeneca, Merck, and Pfizer. Show Less Read more
